Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 11/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 3/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15024266 | 0.95 | GRM5 (0.72) | GRM5 | |
| SCHEMBL15024530 | 0.91 | GRM5 (0.63) | GRM5GRIN2BGRIN1CYP2C9KCNH2 | |
| SCHEMBL15024405 | 0.91 | GRM5 (0.61) | GRM5GRIN2BGRIN1CYP2C9KCNH2 | |
| SCHEMBL15024519 | 0.90 | GRM5 (0.60) | GRM5GRIN2BGRIN1CYP2C9KCNH2 | |
| SCHEMBL15024333 | 0.89 | GRM5 (0.64) | GRM5DPP4DPP8DPP9DPP7 | |
| SCHEMBL15024518 | 0.89 | GRM5 (0.60) | GRM5GRIN2BGRIN1CYP2C9KCNH2 | |
| SCHEMBL15024531 | 0.88 | GRM5 (0.59) | GRM5GRIN2BGRIN1CYP2C9KCNH2 | |
| SCHEMBL15024497 | 0.88 | GRM5 (0.58) | GRM5GRIN2BGRIN1CYP2C9KCNH2 | |
| SCHEMBL15024521 | 0.88 | GRM5 (0.58) | GRM5GRIN2BGRIN1CYP2C9KCNH2 | |
| SCHEMBL15024272 | 0.88 | GRM5 (0.58) | GRM5GRIN2BGRIN1CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642774-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-8642774-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-20130150341-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150341-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150341-A1 | NOVEL COMPOUNDS | GRM5, GRM1, GRIK5 | GRM5 1/4885GRIN2B 8/4885GRIN1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.